Is APRI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

857 people get APRI articles and Market Currents by email alert.

Get email alerts on APRI »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Apricus Biosciences: A Transformative Year Ahead
Chemistfrog • Mon, Apr 1 • 19 Comments
Smart Stocks Watch: Apricus Biosciences
OneMedPlace • Fri, Sep 21, 2012 • 3 Comments
Apricus Biosciences; Vitaros Has Great Potential
Roy Manning III • Sun, Apr 22, 2012 • 16 Comments
Apricus Biosciences' Promising Pipeline Points To A Bright Future
Dustin Moore • Thu, Jan 19, 2012 • 17 Comments
The Truth About Vitaros
Dustin Moore • Tue, Sep 20, 2011 • 27 Comments
Apricus Biosciences Quietly Rising To Top Of Biotech World
Chemistfrog • Wed, Aug 31, 2011 • 3 Comments
Apricus Biosciences: A Victim of Market Hysteria
Dustin Moore • Wed, Aug 10, 2011 • 1 Comment
With Sale of Subsidiary, It's Game Time for Apricus Biosciences
VFC's Stock House • Wed, Jul 6, 2011 • 1 Comment
Apricus Bio Moves Forward With Viagra Competitor Vitaros
Dustin Moore • Wed, Jun 15, 2011 • 7 Comments
Apricus: Making Movies With Critical Events Ahead
VFC's Stock House • Thu, Jun 2, 2011 • 1 Comment
Short-Term Events Could Propel Apricus Higher
VFC's Stock House • Thu, May 19, 2011 • 1 Comment
Apricus Jumps in Anticipation of Quarterly Earnings
VFC's Stock House • Wed, May 11, 2011
Contrasting Opinions on Apricus Are to Be Expected
VFC's Stock House • Thu, Apr 28, 2011
Apricus Trades Higher on Long Term
VFC's Stock House • Mon, Apr 18, 2011 • 2 Comments
Apricus Biosciences: Great Pipeline at a Good Price
Chemistfrog • Mon, Mar 7, 2011 • 1 Comment
Apricus Bio Seeks to Penetrate Untapped Sexual Dysfunction Market
Dustin Moore • Wed, Feb 23, 2011 • 4 Comments
Apricus Bioscience: A Plethora of Pipeline Products With Market Moving Potential
VFC's Stock House • Sun, Feb 20, 2011 • 2 Comments
Apricus Clinical Pipeline Nearing Groundbreaking FDA Catalysts
TheMarketFinancial • Wed, Feb 16, 2011 • 7 Comments
Groundbreaking Drug, Solid Management Make Apricus Bio a Compelling Buy
Dustin Moore • Fri, Nov 19, 2010 • 25 Comments

To learn more about Seeking Alpha Pro, click here.

Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs
Brian L. Wilson • Tue, May 7 • 5 Comments
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
Small-Pharma Watch List: Week Of January 28th
Chemistfrog • Mon, Jan 28 • 11 Comments
'Top Of The Class' Small Pharma Investments For 2013
Chemistfrog • Mon, Jan 14 • 25 Comments
5 Healthcare Companies With Insider Buying Filed On August 20 - 22
Markus Aarnio • Thu, Aug 23, 2012 • 17 Comments
Alexza Pharmaceuticals Reiterated With An Outperform At JMP Securities
Ben Yoffe • Fri, Aug 10, 2012 • 10 Comments
2 Potentially Solid Transdermal Drug Biotechs With Catalysts For 2012
Chemistfrog • Tue, Jan 31, 2012 • 7 Comments
Stocks To Watch For The Week Ahead
VFC's Stock House • Sun, Oct 23, 2011 • 5 Comments
Healthcare Stocks To Watch This Week
VFC's Stock House • Wed, Sep 7, 2011 • 5 Comments
6 Healthcare Stocks Primed For A Rebound
VFC's Stock House • Fri, Aug 26, 2011 • 5 Comments
Stocks To Watch This Week
VFC's Stock House • Tue, Aug 23, 2011 • 1 Comment
Stocks to Watch This Week: June 20-24
VFC's Stock House • Mon, Jun 20, 2011 • 2 Comments
Why 2011 Could Be a Big Year for Pharmaceutical M&A
VFC's Stock House • Sat, Apr 23, 2011 • 10 Comments
Apricus Biosciences: All Grown Up and Attractive for Potential Buyers?
VFC's Stock House • Tue, Mar 8, 2011 • 3 Comments
Amarin Sliding but With Prospects: Time to Buy?
VFC's Stock House • Tue, Mar 1, 2011 • 11 Comments
Undervalued Apricus Bio Poised to Follow Threshold Pharma in Receiving SPA Approval
TheMarketFinancial • Thu, Feb 17, 2011
Healthcare Headlines: Santarus Rallies, Amgen Announces Results
M. E. Garza • Wed, Oct 6, 2010 • 3 Comments

Apricus Biosciences, Inc. - Special Call
Mon, Jun 10 • 1 Comment
Apricus Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10
Apricus Biosciences Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 18
Apricus Biosciences Management Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
Apricus Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Sat, Aug 11, 2012

Apricus Biosciences Receives European Approval for Vitaros(R) for the Treatment of Erectile Dysfunction

GlobeNewswire (Jun 10, 2013)
Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and Warrants

GlobeNewswire (May 23, 2013)
Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire (May 22, 2013)
Apricus Biosciences Provides First Quarter 2013 Corporate Update

GlobeNewswire (May 10, 2013)
Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call

GlobeNewswire (May 7, 2013)
Apricus Biosciences Announces Poster Presentation of Vitaros(R) Data in Men Previously Unresponsive to PDE-5 Inhibitors at American Urological Association Annual Meeting

GlobeNewswire (May 7, 2013)
Apricus Biosciences to Present at 2013 BIO International Convention

GlobeNewswire (Apr 18, 2013)
Apricus Biosciences Announces Sale of Non-Core Assets

GlobeNewswire (Apr 1, 2013)
Apricus Biosciences Provides Corporate Update; Files Annual Report for Quarter and Year Ended December 31, 2012

GlobeNewswire (Mar 18, 2013)
Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer

GlobeNewswire (Mar 18, 2013)
Apricus Biosciences Announces 2012 Year End Financial Results Conference Call

GlobeNewswire (Mar 14, 2013)
Apricus Biosciences Announces Ceasing of Financing of French Subsidiaries

GlobeNewswire (Mar 14, 2013)
Apricus Biosciences to Present at the 25th Annual ROTH Conference

GlobeNewswire (Mar 13, 2013)
Apricus Biosciences to Present at BIO-Europe Spring 2013

GlobeNewswire (Mar 7, 2013)
Apricus Biosciences to Present at the 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
Apricus Biosciences Announces Corporate Goals for 2013

GlobeNewswire (Jan 3, 2013)
Apricus Biosciences to Present at the 24th Annual Piper Jaffray Healthcare Conference

GlobeNewswire (Nov 21, 2012)
Apricus Biosciences' Executives to Present at Two Upcoming Conferences

GlobeNewswire (Nov 8, 2012)
Apricus Biosciences Announces Third Quarter 2012 Financial Results Conference Call

GlobeNewswire (Nov 7, 2012)
Apricus Biosciences Announces Management Changes

GlobeNewswire (Nov 6, 2012)

APRI vs. ETF Alternatives

Company Description

Currently, there's no company description for APRI.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 10, 9:10 AM Premarket gainers: SGOC +18%. APRI +15%.
Losers: DVAX -26%. OSH -25%. Comment! [On the Move]
Monday, June 10, 7:37 AM Via the European Decentralized Procedure (Netherlands is the Reference Member State), Apricus (APRI) gets its ED treatment Vitaros approved. The company believes it will "capture a significant share of the ~$1B PDE-5 inhibitor market." APRI says it will work with partners Sandoz, Takeda (TKPHF.PK), and Bracco to obtain national phase approvals. Shares +9.38% premarket. (PR) Comment! [Healthcare, On the Move]
Thursday, May 23, 2:57 PM Apricus Biosciences (APRI -19.4%) tanks after pricing 6M common shares at $2.85, a 13% discount to the closing price of $3.30 on Wednesday. The company also sold warrants to purchase up to 3M shares of common stock and plans to raise a total of $15.8 million net of expenses. The shares of stock and warrants are immediately separable and will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.40 per share. Comment! [Healthcare, On the Move]
Thursday, May 23, 12:45 PM Midday top 10 gainers: ESMC +52%. HIHO +43%. CNIT +23%. RUE +23%. GAME +16%. HPQ +14%. JRJC +13%. PTIX +13%. HSOL +13%. CHYR +13%.
Midday top 10 Losers: RVM -22%. APRI -21%. CRUS -17%. BOSC -15%. NSPR -15%. MTEX -12%. SHIP -11%. IX -10%. EDMC -10%. AERL -10%. 1 Comment [On the Move]
Wednesday, May 22, 6:19 PM Apricus Biosciences (APRI) gets slammed in the post session after anouncing a public offering of common stock and warrants, with a 30-day option to purchase additional shares and warrants to cover over-allotments, if any. Lazard Capital Markets is acting as sole book-running manager. Shares -13% AH. Comment! [Healthcare, On the Move]
Wednesday, May 15, 2:29 PM Apricus Biosciences (APRI +15%) ramps higher today after its board of directors votes to terminate the company's shareholder rights agreement. With the poison pill out of the way, investors appear to be placing bets on a future takeout of the company. Comment! [Healthcare, On the Move]
Tuesday, April 2, 12:16 PM Apricus Biosciences (APRI +2%) moves up today after reporting the sale of some non-core assets: Totect, a marketed, injectable treatment for anthracycline extravasation, and NitroMist, an FDA-approved nitrate vasodilator that treats angina pectoris. Financial details of the sale were not disclosed Comment! [Healthcare, On the Move]
Monday, April 1, 4:50 PM Apricus Biosciences (APRI) moves ahead with its planned divestiture of non-core assets as it sells its extravasation injection Totect to Biocodex and its nitrate vasodilator NitroMist to Mist Pharmaceuticals. The company says it sold the products "in line with their initial up-front purchase price." Comment! [Healthcare]
Monday, March 18, 12:31 PM Apricus Biosciences (APRI -4%) slips today after the company gives an update on corporate activities and announces it's appointed Richard Pascoe, a 20-year veteran in the biopharmaceutical industry, as its new CEO as the company begins development and marketing of Vitaros and Femprox. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Wednesday, November 7, 2012, 12:45 PM Midday top 10 gainers: CALI +89%. SRT +22%. VHC +21%. AMRS +20%. HDY +19%. PKT +16%. FCAL +14%. CNTF +12%. MKTG +10%. SGI +10%. Midday top 10 Losers: QLTY -34%. PLXS -28%. STEC -23%. JRCC -21%. PQ -18%. APRI -18%. FRM -17%. RBCN -17%. PHMD -17%. THQI -17%. Comment!
Tuesday, November 6, 2012, 5:56 PM Apricus Biosciences (APRI) says that its director, president and CEO, Bassam Damaj, Ph.D., has resigned effective immediately, and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO with pharmaceutical industry experience. Shares -2.3% AH. 1 Comment [Healthcare, On the Move]
Monday, October 1, 2012, 8:00 AM Shares of Apricus Biosciences (APRI) soar 11.1% premarket after the company announces that it will file a new drug submission in Canada for MycoVa in Q4 of 2013. In advanced testing, MycoVa has shown an ability to kill nail fungus and improve the appearance of nails. Comment! [On the Move, Healthcare]
Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
Thursday, September 13, 2012, 9:10 AM Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move]
Monday, July 16, 2012, 5:38 PM Apricus Biosciences (APRI) files a 3.7M share registration statement. Stock -5.6% AH. 1 Comment [Healthcare, On the Move]

Dustin Moore
$APRI quietly moving higher after brutal and oddly-timed dilution, just ahead of EMA decision of its drug Vitaros
May 31, 12:24 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dustin Moore
$APRI starting run up to EU decision set in a few weeks? I'll explain why approval is likely soon...
May 15, 12:23 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

rvanlith
Looks like Vitaros will finally be sold in Canada now. $APRI , Here we go. http://bit.ly/UBRkyd
12/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dustin Moore
$APRI Vitaros presentation shows saftey profile/clinically sustained improvement for patients with ED http://bit.ly/Un1gI3
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
10/18/12 2:36P ET: { Results Update } We decided to exit APRI today with a nominal gain. http://bit.ly/t7mrwo
10/18/12
Reply (2)

• !Report Abuse
View all 2 replies
Justin M. Hall: Near-term, APRI is likely to head south, possibly as low as $2.25 or so. We may revisit this stock again at lower levels.
10/18/12
• !Report Abuse
bhowell350: looks like you made a good call.. Is this now the time to reenter? Abbot is now saying a first half 2013 intro for Vitaros in Canada
11/20/12
• !Report Abuse
Add a reply...

140 characters

Dustin Moore
$APRI SEC filing suggests positive guidance re $WCRX Vitaros ED drug http://bit.ly/SKQqhl
10/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dustin Moore
Ascendiant Capital issues strong-buy for Apricus $APRI 3.38 (+8.33%) - Price Tartget $8 http://bit.ly/N2Y5lC
7/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Waiting for huge catalyst on APRI. Should be any day that Europe makes decision on Vitaros.
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
Roy Manning III: It was announced that Vitaros European approval would be delayed at least 8 months. Check the quarterly report and conference call.
3/29/12
• !Report Abuse
Add a reply...

140 characters

Todd Theman
wondering when fortunes will turn around for APRI...need to see some sales numbers, but anticipating a nice return from these levels
3/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

rvanlith
What is with APRI today?
3/22/12
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: "European Patent Office allows patent application". (Briefing.com)
3/22/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Justin M. Hall
10/18/12 2:36P ET: { Results Update } We decided to exit APRI today with a nominal gain. http://bit.ly/t7mrwo
10/18/12
Reply (2)

• !Report Abuse
View all 2 replies
Justin M. Hall: Near-term, APRI is likely to head south, possibly as low as $2.25 or so. We may revisit this stock again at lower levels.
10/18/12
• !Report Abuse
bhowell350: looks like you made a good call.. Is this now the time to reenter? Abbot is now saying a first half 2013 intro for Vitaros in Canada
11/20/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
Waiting for huge catalyst on APRI. Should be any day that Europe makes decision on Vitaros.
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
Roy Manning III: It was announced that Vitaros European approval would be delayed at least 8 months. Check the quarterly report and conference call.
3/29/12
• !Report Abuse
Add a reply...

140 characters

rvanlith
What is with APRI today?
3/22/12
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: "European Patent Office allows patent application". (Briefing.com)
3/22/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology
3/5/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
3/5/12
• !Report Abuse
Add a reply...

140 characters

APRI Apricus Biosciences, Inc

APRI

Apricus Biosciences, Inc